Literature DB >> 8148468

Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process.

T K Walters1, D A Gorog, R F Wood.   

Abstract

Vascular injury, activation of the coagulation system and thrombosis are common initial events in the accelerated atherosclerotic process. The role of thrombin generated at the site of aortic injury in the subsequent neointimal proliferation was studied in rabbits (n = 16) 3 weeks after balloon catheter injury. In half of these animals, potent thrombin antagonists, r-hirudin and P-PACK, were administered to prevent acute thrombotic events. Compared to aortas with intact endothelium (n = 8), aortas de-endothelialised 21 days earlier showed neointimal hyperplasia as measured by the intimal/medial ratio (0.68 vs. 0.04, injured vs. normal aortas) and an increase in both total cholesterol (4.08 vs. 3.31 mg/g, p < 0.05) and lipid peroxide content (31.3 vs. 1.1 nmol/g; p < 0.001). Neointimal hyperplasia following endothelial denudation was inhibited in rabbits treated with thrombin-antagonists (0.27 vs. 0.68, treated vs. untreated, p = 0.012) and neither total cholesterol (3.48 mg/g) nor lipid peroxide content (1.5 nmol/g) differed significantly from that of intact arteries. By demonstrating a strong relationship between thrombin generation following de-endothelialisation and the progressive intimal proliferation, this study supports the hypothesis that thrombin is an important contributor to restenosis after vascular injury. The highly atherogenic lipid peroxidation seems to be linked to the early, thrombin-mediated events, as it was completely prevented by adequate thrombin antagonism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148468     DOI: 10.1159/000319584

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  7 in total

1.  Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.

Authors:  E Gandossi; C Lunven; C N Berry
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  The endovascular revolution.

Authors:  T al-Mishlab; T K Walters
Journal:  Ann R Coll Surg Engl       Date:  1997-07       Impact factor: 1.891

3.  Impact of moderate blast exposures on thrombin biomarkers assessed by calibrated automated thrombography in rats.

Authors:  Victor Prima; Victor L Serebruany; Artem Svetlov; Ronald L Hayes; Stanislav I Svetlov
Journal:  J Neurotrauma       Date:  2013-10-04       Impact factor: 5.269

4.  Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells.

Authors:  R P Fabunmi; A H Baker; E J Murray; R F Booth; A C Newby
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

5.  NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.

Authors:  Aleksandr E Vendrov; Nageswara R Madamanchi; Xi-Lin Niu; Kimberly C Molnar; Mason Runge; Cédric Szyndralewiez; Patrick Page; Marschall S Runge
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

6.  Thrombin receptor activation elicits rapid protein tyrosine phosphorylation and stimulation of the raf-1/MAP kinase pathway preceding delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for an obligate autocrine mechanism promoting cell proliferation induced by G-protein-coupled receptor agonist.

Authors:  C J Molloy; J E Pawlowski; D S Taylor; C E Turner; H Weber; M Peluso
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

Review 7.  Golden Needle Mushroom: A Culinary Medicine with Evidenced-Based Biological Activities and Health Promoting Properties.

Authors:  Calyn Tang; Pearl Ching-Xin Hoo; Loh Teng-Hern Tan; Priyia Pusparajah; Tahir Mehmood Khan; Learn-Han Lee; Bey-Hing Goh; Kok-Gan Chan
Journal:  Front Pharmacol       Date:  2016-12-07       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.